ClinicalTrials.gg
CompletedNCT05593029Updated Feb 18, 2026

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

A Phase 2 interventional study of SEP-363856 and Placebo in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 77 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
929
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Depressive Disorder, Major · Otsuka Holdings Co., Ltd..

Enrollment
9th of 40
929 · median 287
Started
2022
with 3 others
Phase 2
7 of 45
none open now
Registered
43rd of 45
by date

Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 9th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2022, is one of 7 in phase 2, and was the 43rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd. is open now. The open studies under Depressive Disorder, Major, anywhere →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate response to prior ADT therapy.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • MDD
  • SEP-363856
  • Antidepressant Therapy
  • ADT
  • Depression
  • Depressive Disorder
  • Major Mood Disorders
  • Mental Disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female subjects between 18-65 years of age, with a primary diagnosis of major depressive disorder and in a current major depressive episode
  • Current major depressive episode must be at least 8 weeks and no longer than 2 years in duration
  • History of an inadequate response to at least 1 and no more than 3 antidepressant treatments in the current major depressive episode

Exclusion criteria

Exclusion Criteria:

  • Subjects who report an inadequate response to more than 3 antidepressant treatments in the current episode
  • Subjects with a lifetime history of schizophrenia spectrum or other psychotic disorder, bipolar or related disorder, major or mild neurocognitive disorder, neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent/ follow study directions/ or otherwise safely participate in the study, borderline or antisocial personality disorder.
  • Subjects with a current diagnosis of post-traumatic stress disorder, obsessive compulsive disorder, panic disorder, or eating disorder (including anorexia nervosa or bulimia).
  • Sexually active subjects, who could become pregnant, not agreeing to practice 2 sponsor approved methods of or remain abstinent during the trial and for 30 days (females) or 90 days (males) after last dose of study drug.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
929 participants (actual)

Study arms

  • Experimental
    SEP-363856 & ADT (Antidepressant Therapy)

    Drug: SEP-363856

  • Placebo comparator
    Placebo & ADT (Antidepressant Therapy)

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Montgomery Åsberg Depression Rating Scale (MADRS)

    Change from the baseline to the Montgomery Åsberg Depression Rating Scale (MADRS) total score. The Montgomery Åsberg Depression Rating Scale consists of 10 items, each rated from 0 to 6 (for a total score of 0 to 60). A higher score represents a higher severity of the level of depression.

    Time frame: From baseline to week 14

Secondary outcomes

  1. Clinical Global Impression - Severity of Illness (CGI-S)

    Change from baseline in the Clinical Global Impression - Severity of Illness (CGI-S). Clinical Global Impression - Severity of Illness will be measured on a scale from 1-7 where a higher score represents a higher severity of disease.

    Time frame: From baseline to week 14

07

Study locations

77 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Scottsdale Clinical Research
    Scottsdale, Arizona 85260, United States
  • DelSol Research
    Tucson, Arizona 85715, United States
  • Pillar Clinical Research
    Bentonville, Arkansas 72712, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Wr-Pri, Llc
    Encino, California 91316, United States
  • Collaborative NeuroScience Research , LLC
    Garden Grove, California 92845, United States
  • Alliance Research
    Long Beach, California 90807, United States
  • ATP Clinical Research, Inc.
    Orange, California 92868, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • California Mental Behavioral Health
    Santee, California 92071, United States
  • Schuster Medical Research Institute SMRI
    Sherman Oaks, California 91403, United States
  • Viking Clinical Research
    Temecula, California 92591, United States
  • Collaborative Neuroscience Research LLC
    Torrance, California 90504, United States
  • Sunwise Clinical Research with is in Lafayette, CA
    Walnut Creek, California 94596, United States
  • Institute of Living Hartford Hospital
    Hartford, Connecticut 06106, United States
  • Clinical Neuroscience Solutions Inc.
    Jacksonville, Florida 32256, United States
  • K2 Medical Research
    Maitland, Florida 32751, United States
  • Central Miami Medical Institute
    Miami, Florida 33125, United States
  • Clinical Neuroscience Solutions Inc. dba CNS Healthcare
    Orlando, Florida 32801, United States
  • Combined Research Orlando Phase I-IV
    Orlando, Florida 32807, United States
  • K2 Medical Research
    Tampa, Florida 33607, United States
  • Interventional Psychiatry of Tampa Bay
    Tampa, Florida 33629, United States
  • Advanced Discovery Research LLC
    Atlanta, Georgia 30318, United States
  • Renew Health Clinical Research
    Snellville, Georgia 30078, United States
  • MetroMed Clinical Trials
    Chicago, Illinois 60614, United States
  • AMR Convention Research
    Warrenville, Illinois 60555, United States
  • Benchmark Research
    Shreveport, Louisiana 71101, United States
  • Cenexel CBH (CBH Health)
    Gaithersburg, Maryland 20877, United States
  • Copley Clinical
    Boston, Massachusetts 02116, United States
  • Boston Clinical Trials
    Roslindale, Massachusetts 02131, United States
  • Adams Clinical
    Watertown, Massachusetts 02471, United States
  • Vitalix Clinical
    Worcester, Massachusetts 01608, United States
  • Neurobehavioral Medicine Group
    Bloomfield Hills, Michigan 48302, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Integrative Clinical Trials
    Brooklyn, New York 11229, United States
  • Basil Clinical
    Inwood, New York 11096, United States
  • Berman Clinical
    New York, New York 10029, United States
  • Manhattan Behavioral Medicine PLLC
    New York, New York 10036, United States
  • The Medical Research Network, LLC
    New York, New York 10128, United States
  • Patient Priority Clinical Studies LLC
    Cincinnati, Ohio 45215, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73116, United States
  • Suburban Research Associates
    West Chester, Pennsylvania 19380, United States
  • Clinical Neuroscience Solutions Inc.
    Memphis, Tennessee 38119, United States
  • Donald J. Garcia, Jr., MD, PA
    Austin, Texas 78737, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75251, United States
  • North Texas Clinical Trials
    Fort Worth, Texas 76104, United States
  • DM Clinical Research - Belliare
    Houston, Texas 77081, United States
  • Psychiatric And Behavioral Solutions, LLC
    Millcreek, Utah 84124, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
  • Diagnostic Consultive Center Higya AD
    Pazardzhik, 4400, Bulgaria
  • Ambulatory for Group Practice for Specialized Psychiatrics Help PHILIPOPOLIS OOD
    Plovdiv, 4002, Bulgaria
  • Medical Center Sveti Naum
    Sofia, 1113, Bulgaria
  • DCC-Mladost M OOD
    Varna, 9020, Bulgaria
  • Mental Health Center Vratsa
    Vratsa, 3000, Bulgaria
  • Chatham-Kent Clinical Trials Research Centre
    Chatham, Ontario N7L 1C1, Canada
  • Institute of Mental Health Research IMHR
    Ottawa, Ontario K1Z 7K4, Canada
  • Centre for Addiction and Mental Health (CAMH & University of Toronto)
    Toronto, Ontario M6J 1H4, Canada
  • BRAIN-SOULTHERAPY s.r.o.
    Kladno, Central Bohemia 272 01, Czechia
  • A-Shine s.r.o.
    Ptzen, Plzeň Region 30100, Czechia
  • National Institute of Mental Health
    Klecany, 25067, Czechia
  • Clintrial s.r.o.
    Prague, 10000, Czechia
  • Velocity Clinical Research Wiesbaden
    Wiesbaden, Hesse 65189, Germany
  • Pharmakologisches Studienzentrum Chemnitz GmbH
    Chemnitz, MA 09111, Germany
  • Private Practice Kusserow
    Stralsund, Mecklenburg-Vorpommern 18439, Germany
  • Somni Bene Institut for Medical Research
    Schwerin, Mecklenburg 19053, Germany
  • Arztepartnerschaft Dr. med. J. Springhub/ W. Schwarz-Studienzentrum Nord-West
    Westerstede, 26655, Germany
  • ClinExpert Kft.
    Budapest, 1033, Hungary
  • Semmelweis University
    Budapest, M6J 1H4, Hungary
  • Praktyka Lekarska Malgorzata Wojtanowska-Bogacka
    Poznan, Greater Poland Voivodeship 60-192, Poland
  • Osrodek Badan Klinicznych CLINSANTE
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-794, Poland
  • MlynowaMed - Bialystok
    Bialystok, OH 15-404, Poland
  • Centrum Medyczne Luxmed Sp.z. o.o.
    Lublin, 20-109, Poland
  • Indywidualna SpecjalistycznaPraktyka Lekarska AgnieszkaRemlinger-Molenda
    Szkolkarska 32, 62-002, Poland
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Nov 2025, 35 months.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 35 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2022
First posted
Oct 25, 2022
StartActual
Nov 9, 2022
Primary completionActual
Nov 6, 2025
CompletionActual
Nov 13, 2025
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05593029
Responsible party
Sponsor
First posted
Oct 25, 2022
Start date
Nov 9, 2022
Primary completion
Nov 6, 2025
Completion
Nov 13, 2025
Last update
Feb 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion